Ulisse BioMed

Ulisse BioMed is a manufacturer of biological drug monitoring and molecular diagnostics. Its Sagitta platform offers molecular diagnostic test kits for the diagnosis and detection of respiratory infections, HPV, and nucleic acid extraction. The company also provides a drug monitoring platform with NanoHybrid technology to detect specific antibodies and protein analytes directly from serum or whole blood. Ulisse BioMed is developing a full range of products to monitor patients prescribed with biologics or biosimilars, supporting personalized medicine through therapeutic drug monitoring. Founded in 2015 and headquartered in Udine, Italy, Ulisse BioMed has raised approximately 17.6 million at the Series B stage with investors including Europa and Global Corporate Finance.